DUBLIN, Ireland and CHICAGO, Sept. 19, 2022 (GLOBE NEWSWIRE) — Iterum Therapeutics plc ITRM (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next-generation oral and intravenous antibiotics for the treatment of infections caused by multidrug-resistant pathogens in both the community and hospital settings , today announced the U.S. Patent and The Trademark Office has issued the Company a Statement of Acceptance of U.S. Patent Application No. 16/972,300, entitled “Combinations of Beta-Lactam Compounds and Probenecid and Uses of There,” which relates to the Composition of the bilayer tablet of sulopenem etzadroxil and probenecid (“oral sulopenem”). ) and associated uses.

“This patent approval provides up to 10 years of additional patent protection for our lead candidate and is a significant milestone for Iterum in protecting the long-term commercial potential of oral sulopenem, which, if approved, would be the first orally available penem in the US and the first new oral treatment in uncomplicated urinary tract infections for over 20 years,” said Corey Fishman, Chief Executive Officer. “We remain focused on the preparation of our planned pivotal Phase 3 clinical trial of oral sulopenem in the treatment of uncomplicated urinary tract infections and look forward to beginning enrollment In the coming weeks.”

This Notice of Allowance concludes the substantive examination of the patent application and, upon completion of the administrative procedures, results in the grant of a US patent. The US patent which is to be issued from this application will expire at the earliest in 2039, barring any extensions. The existing patent protection for sulopenem etzadroxil is expected to expire in 2029, subject to a possible extension.

The Company’s patent portfolio also includes pending patent applications outside the United States, including Europe and China, which were filed upon receipt of written opinion from the International Searching Authority showing that multiple claims…